Jubilant Pharmova Ltd
NSE:JUBLPHARMA

Watchlist Manager
Jubilant Pharmova Ltd Logo
Jubilant Pharmova Ltd
NSE:JUBLPHARMA
Watchlist
Price: 890.05 INR 2.56%
Market Cap: 141B INR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

JUBLPHARMA Price Targets Summary
Jubilant Pharmova Ltd

Wall Street analysts forecast JUBLPHARMA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for JUBLPHARMA is 1 373.6 INR with a low forecast of 1 247.35 INR and a high forecast of 1 491 INR.

JUBLPHARMA Lowest Forecast
Wall Street Target
1 247.35 INR
40% Upside
JUBLPHARMA Average Forecast
Wall Street Target
1 373.6 INR
54% Upside
JUBLPHARMA Highest Forecast
Wall Street Target
1 491 INR
68% Upside
Lowest
Price Target
1 247.35 INR
40% Upside
Average
Price Target
1 373.6 INR
54% Upside
Highest
Price Target
1 491 INR
68% Upside
Jubilant Pharmova Ltd Competitors:
Price Targets
300723
Yipinhong Pharmaceutical Co Ltd
37% Downside
IPN
Ipsen SA
28% Upside
6622
Zhaoke Ophthalmology Ltd
55% Upside
M
MBX
MBX Biosciences Inc
243% Upside
300723
Yipinhong Pharmaceutical Co Ltd
37% Downside
IPN
Ipsen SA
28% Upside
6622
Zhaoke Ophthalmology Ltd
55% Upside
M
MBX
MBX Biosciences Inc
243% Upside
600085
Beijing Tongrentang Co Ltd
23% Upside
128940
Hanmi Pharm Co Ltd
32% Upside

Revenue
Forecast

Revenue Estimate
Jubilant Pharmova Ltd

For the last 8 years the compound annual growth rate for Jubilant Pharmova Ltd's revenue is 2%. The projected CAGR for the next 3 years is 11%.

2%
Past Growth
11%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Jubilant Pharmova Ltd

For the last 8 years the compound annual growth rate for Jubilant Pharmova Ltd's operating income is -8%. The projected CAGR for the next 3 years is 30%.

-8%
Past Growth
30%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Jubilant Pharmova Ltd

For the last 8 years the compound annual growth rate for Jubilant Pharmova Ltd's net income is -18%. The projected CAGR for the next 3 years is 116%.

-18%
Past Growth
116%
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

See Also

Summary
JUBLPHARMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
JUBLPHARMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
JUBLPHARMA stock valuation using valuation multiples.
Wall Street Estimates
JUBLPHARMA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
JUBLPHARMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is JUBLPHARMA's stock price target?
Price Target
1 373.6 INR

According to Wall Street analysts, the average 1-year price target for JUBLPHARMA is 1 373.6 INR with a low forecast of 1 247.35 INR and a high forecast of 1 491 INR.

What is Jubilant Pharmova Ltd's Revenue forecast?
Projected CAGR
11%

For the last 8 years the compound annual growth rate for Jubilant Pharmova Ltd's revenue is 2%. The projected CAGR for the next 3 years is 11%.

What is Jubilant Pharmova Ltd's Operating Income forecast?
Projected CAGR
30%

For the last 8 years the compound annual growth rate for Jubilant Pharmova Ltd's operating income is -8%. The projected CAGR for the next 3 years is 30%.

What is Jubilant Pharmova Ltd's Net Income forecast?
Projected CAGR
116%

For the last 8 years the compound annual growth rate for Jubilant Pharmova Ltd's net income is -18%. The projected CAGR for the next 3 years is 116%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 254,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.